Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2019-09-12

Clinical Trial Update: A Comparison of Two Doses of Pemetrexed in Patients Who Have Lung Cancer [Phase 3]

View source ↗

Summary

A Phase 3 trial comparing two doses of pemetrexed in non-small cell lung cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Pemetrexed (pemetrexed)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Non-Small Cell Lung Cancer | Phase 3 | Status: COMPLETED